The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab (TCH) activity in HER2-positive early breast cancer: Results after a median follow-up of 4.5 years.
 
Hans-Christian Kolberg
Honoraria - Carl Zeiss Meditec; Genomic Health; GlaxoSmithKline; Novartis; Pfizer; Roche; Teva; Theraclion
Consulting or Advisory Role - Carl Zeiss Meditec; Genomic Health; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Amgen; Novartis
 
Leyla Akpolat-Basci
No Relationships to Disclose
 
Miltiades Stephanou
No Relationships to Disclose
 
Carla Hannig
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); CSL Behring (Inst); Medac (Inst); Novartis (Inst); Roche (Inst)
 
Cornelia Liedtke
Honoraria - Amgen; AstraZeneca; Celgene; Eisai; Genomic Health; GlaxoSmithKline; PharmaMar; Roche
Consulting or Advisory Role - Genomic Health; Novartis; Pierre Fabre; Roche; Teva
Speakers' Bureau - Genomic Health
Research Funding - Boehringer Ingelheim; Eisai; Novartis; Roche
Travel, Accommodations, Expenses - Celgene; PharmaMar; Roche; Teva